Modulation of LMNA splicing as a strategy to treat prelamin A diseases

Journal of Clinical Investigation

Volumn 126, Issue 4, 2016, Pages 1592-1602

  Lee, John M ^a,d   Nobumori, Chika ^a   Tu, Yiping ^a   Choi, Catherine ^a   Yang, Shao H ^a   Jung, Hea Jin ^a   Vickers, Timothy A ^b   Rigo, Frank ^b   Bennett, C Frank ^b   Young, Stephen G ^a,c   Fong, Loren G ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ISIS PHARMACEUTICALS   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d ST LUKE S EPISCOPAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; LAMIN; LAMIN A; LAMIN C; MESSENGER RNA; PRELAMIN A; PROGERIN; PROTEIN; SERINE ARGININE RICH SPLICING FACTOR; SERINE ARGININE RICH SPLICING FACTOR 2; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; ANTISENSE OLIGODEOXYNUCLEOTIDE; LMNA PROTEIN, MOUSE; NUCLEAR PROTEIN; RIBONUCLEOPROTEIN; SFRS2 PROTEIN, MOUSE;

ALTERNATIVE RNA SPLICING; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING SITE; CONTROLLED STUDY; DNA SEQUENCE; EMBRYO; EXON; FIBROBLAST; FIBROBLAST CULTURE; GENE; GENE SILENCING; HUMAN; HUMAN CELL; IN VIVO STUDY; LMNA GENE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGERIA; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; DISEASE MODEL; DRUG EFFECTS; GENETICS; METABOLISM; MUTATION; TRANSGENIC MOUSE;

ALTERNATIVE SPLICING; ANIMALS; DISEASE MODELS, ANIMAL; EXONS; GENE KNOCKDOWN TECHNIQUES; HUMANS; LAMIN TYPE A; MICE; MICE, TRANSGENIC; MUTATION; NUCLEAR PROTEINS; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; PROGERIA; RIBONUCLEOPROTEINS; RNA, MESSENGER; SERINE-ARGININE SPLICING FACTORS;

EID: 84964663129     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI85908     Document Type: Article

References (42)

1. Worman HJ, Bonne G. "Laminopathies": A wide spectrum of human diseases. Exp Cell Res. 2007;313(10):2121-2133.
2. Gerace L, Blum A, Blobel G. Immunocytochemical localization of the major polypeptides of the nuclear pore complex-lamina fraction. Interphase and mitotic distribution. J Cell Biol. 1978;79(2 pt 1):546-566.
3. Lehner CF, Kurer V, Eppenberger HM, Nigg EA. The nuclear lamin protein family in higher vertebrates. Identification of quantitatively minor lamin proteins by monoclonal antibodies. J Biol Chem. 1986;261(28):13293-13301.
4. Fisher DZ, Chaudhary N, Blobel G. cDNA sequencing of nuclear lamins A and C reveals primary and secondary structural homology to intermediate filament proteins. Proc Natl Acad Sci U S A. 1986;83(17):6450-6454.
5. McKeon FD, Kirschner MW, Caput D. Homologies in both primary and secondary structure between nuclear envelope and intermediate filament proteins. Nature. 1986;319(6053):463-468.
6. Kolb T, Maass K, Hergt M, Aebi U, Herrmann H. Lamin A and lamin C form homodimers and coexist in higher complex forms both in the nucleoplasmic fraction and in the lamina of cultured human cells. Nucleus. 2011;2(5):425-433.
7. Lin F, Worman HJ. Structural organization of the human gene encoding nuclear lamin A and nuclear lamin C. J Biol Chem. 1993;268(22):16321-16326.
8. Weber K, Plessmann U, Traub P. Maturation of nuclear lamin A involves a specific carboxy-terminal trimming, which removes the polyisoprenylation site from the precursor; implications for the structure of the nuclear lamina. FEBS Lett. 1989;257(2):411-414.
9. Sinensky M, Fantle K, Trujillo M, McLain T, Kupfer A, Dalton M. The processing pathway of prelamin A. J Cell Sci. 1994;107(pt 1):61-67.
10. Lutz RJ, Trujillo MA, Denham KS, Wenger L, Sinensky M. Nucleoplasmic localization of prelamin A: Implications for prenylation-dependent lamin A assembly into the nuclear lamina. Proc Natl Acad Sci U S A. 1992;89(12):3000-3004.
11. Young SG, Fong LG, Michaelis S. Prelamin A, Zmpste24, misshapen cell nuclei, and progeria - new evidence suggesting that protein farnesylation could be important for disease pathogenesis. J Lipid Res. 2005;46(12):2531-2558.
12. Sullivan T, et al. Loss of A-type lamin expression compromises nuclear envelope integrity leading to muscular dystrophy. J Cell Biol. 1999;147(5):913-919.
13. Fong LG, et al. Prelamin A and lamin A appear to be dispensable in the nuclear lamina. J Clin Invest. 2006;116(3):743-752.
14. Coffinier C, et al. Direct synthesis of lamin A, bypassing prelamin A processing, causes misshapen nuclei in fibroblasts but no detectable pathology in mice. J Biol Chem. 2010;285(27):20818-20826.
15. Lopez-Mejia IC, et al. Antagonistic functions of LMNA isoforms in energy expenditure and lifespan. EMBO Rep. 2014;15(5):529-539.
16. Schreiber KH, Kennedy BK. When lamins go bad: nuclear structure and disease. Cell. 2013;152(6):1365-1375.
17. de Sandre-Giovannoli A, et al. Lamin A truncation in Hutchinson-Gilford progeria. Science. 2003;300(5628):2055.
18. Eriksson M, et al. Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome. Nature. 2003;423(6937):293-298.
19. Fong LG, et al. Heterozygosity for Lmna deficiency eliminates the progeria-like phenotypes in Zmpste24-deficient mice. Proc Natl Acad Sci U S A. 2004;101(52):18111-18116.
20. Glynn MW, Glover TW. Incomplete processing of mutant lamin A in Hutchinson-Gilford progeria leads to nuclear abnormalities, which are reversed by farnesyltransferase inhibition. Hum Mol Genet. 2005;14(20):2959-2969.
21. Moulson CL, et al. Increased progerin expression associated with unusual LMNA mutations causes severe progeroid syndromes. Hum Mutat. 2007;28(9):882-889.
22. Yang SH, et al. A farnesyltransferase inhibitor improves disease phenotypes in mice with a Hutchinson-Gilford progeria syndrome mutation. J Clin Invest. 2006;116(8):2115-2121.
23. Yang SH, Qiao X, Farber E, Chang SY, Fong LG, Young SG. Eliminating the synthesis of mature lamin A reduces disease phenotypes in mice carrying a Hutchinson-Gilford progeria syndrome allele. J Biol Chem. 2008;283(11):7094-7099.
24. Varela I, et al. Combined treatment with statins and aminobisphosphonates extends longevity in a mouse model of human premature aging. Nat Med. 2008;14(7):767-772.
25. Osorio FG, et al. Splicing-directed therapy in a new mouse model of human accelerated aging. Sci Transl Med. 2011;3(106):106ra7.
26. Yang SH, Qiao X, Fong LG, Young SG. Treatment with a farnesyltransferase inhibitor improves survival in mice with a Hutchinson-Gilford progeria syndrome mutation. Biochim Biophys Acta. 2008;1781(1-2):36-39.
27. Gordon LB, et al. Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci U S A. 2012;109(41):16666-16671.
28. Gordon LB, Massaro J, D'Agostino RB Sr. Campbell SE, Brazier J, Brown WT, Kleinman ME, and Kieran MW. Impact of farnesylation inhibitors on survival in Hutchinson-Gilford progeria syndrome. Circulation. 2014;130(1):27-34.
29. Rigo F, Seth PP, Bennett CF. Antisense oligonucleotide-based therapies for diseases caused by pre-mRNA processing defects. Adv Exp Med Biol. 2014;825:303-352.
30. Bennett CF, Swayze EE. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol. 2010;50:259-293.
31. Scaffidi P, Misteli T. Lamin A-dependent nuclear defects in human aging. Science. 2006;312(5776):1059-1063.
32. Rodriguez S, Coppede F, Sagelius H, Eriksson M. Increased expression of the Hutchinson-Gilford progeria syndrome truncated lamin A transcript during cell aging. Eur J Hum Genet. 2009;17(7):928-937.
33. Singh G, Cooper TA. Minigene reporter for identification and analysis of cis elements and trans factors affecting pre-mRNA splicing. Biotechniques. 2006;41(2):177-181.
34. Bergo MO, et al. Zmpste24 deficiency in mice causes spontaneous bone fractures, muscle weakness, and a prelamin A processing defect. Proc Natl Acad Sci U S A. 2002;99(20):13049-13054.
35. Varga R, et al. Progressive vascular smooth muscle cell defects in a mouse model of Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci U S A. 2006;103(9):3250-3255.
36. van Engelen BG, Muchir A, Hutchison CJ, van der Kooi AJ, Bonne G, Lammens M. The lethal phenotype of a homozygous nonsense mutation in the lamin A/C gene. Neurology. 2005;64(2):374-376.
37. Witten JT, Ule J. Understanding splicing regulation through RNA splicing maps. Trends Genet. 2011;27(3):89-97.
38. Lopez-Meijia IC, et al. A conserved splicing mechanism of the LMNA gene controls premature aging. Hum Mol Genet. 2011;20(23):4540-4555.
39. Hiller M, Zhang Z, Backofen R, Stamm S. Pre-m-RNA secondary structures influence exon recognition. PLoS Genet. 2007;3(11):e204.
40. Graveley BR, Maniatis T. Arginine/serine-rich domains of SR proteins can function as activators of pre-mRNA splicing. Mol Cell. 1998;1(5):765-771.
41. Huang S, et al. Correction of cellular phenotypes of Hutchinson-Gilford Progeria cells by RNA interference. Hum Genet. 2005;118(3-4):444-450.
42. Xiao R, et al. Splicing regulator SC35 is essential for genomic stability and cell proliferation during mammalian organogenesis. Mol Cell Biol. 2007;27(15):5393-5402.